The grant allows both the companies to jointly develop a preclinical program on a potential new treatment for stroke patients.
The program is aimed to deliver NeuroVive’s cyclosporin A drug across the blood-brain barrier in stroke patients using to-BBB’s G-Technology.
to-BBB CSO Pieter Gaillard said NeuroVive’s expertise in the area of acute neurological conditions and their clinical work with NeuroStat in traumatic brain injuries, provides a strong base for this program.
NeuroVive CEO Mikael Bronnegard said they look forward to accelerate the partnership of NeuroVive and to-BBB with the aim to generate therapies for the large stroke market and other acute neurological conditions.